atibuclimab (IC14) / Implicit Biosci - LARVOL DELTA

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy (clinicaltrials.gov) - P1/2 | N=5 | Active, not recruiting | Sponsor: Implicit Bioscience | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiomyopathy • Cardiovascular

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI (clinicaltrials.gov) - P1/2 | N=10 | Recruiting | Sponsor: Implicit Bioscience | Trial completion date: Oct 2025 ➔ Jun 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Myocardial Infarction • CD14

IC14 (atibuclimab) in Arrhythmogenic Cardiomyopathy (clinicaltrials.gov) - P1/2 | N=5 | Recruiting | Sponsor: Implicit Bioscience | Trial completion date: Aug 2025 ➔ Dec 2025 | Trial primary completion date: Feb 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Cardiomyopathy • Cardiovascular

Anti-CD14 Treatment with IC14 in Hospitalized ARDS Patients (clinicaltrials.gov) - P2 | N=56 | Not yet recruiting | Sponsor: Implicit Bioscience | Initiation date: Aug 2024 ➔ May 2025 | Trial primary completion date: Feb 2025 ➔ Jun 2026

Trial initiation date • Trial primary completion date • Acute Lung Injury • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

IC14 for Treatment of Acute Decompensated Heart Failure (clinicaltrials.gov) - P1/2 | N=10 | Recruiting | Sponsor: Implicit Bioscience | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: Implicit Bioscience

New P1/2 trial • Cardiovascular • Myocardial Infarction • CD14

IC14 for Treatment of Acute Decompensated Heart Failure (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: Implicit Bioscience

New P1/2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients (clinicaltrials.gov) - P2 | N=56 | Not yet recruiting | Sponsor: Implicit Bioscience

New P2 trial • Acute Lung Injury • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Anti-CD14 Treatment and Mortality in Severe COVID-19: A Secondary Subgroup Analysis by Baseline Plasma Presepsin Levels in the I-SPY COVID Adaptive Platform Trial (ATS 2024) - "Our findings suggest that a baseline marker of CD14-pathway activity, presepsin, might identify severely ill patients with viral pneumonia more likely to respond to therapy blocking CD14-mediated inflammation. Although these analyses were based on small sample size, additional studies should be conducted to further test the hypothesis that presepsin-guided IC14 therapy is beneficial in severe viral pneumonia."

Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • CD14

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy (clinicaltrials.gov) - P1/2 | N=5 | Recruiting | Sponsor: Implicit Bioscience | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy (clinicaltrials.gov) - P1/2 | N=5 | Not yet recruiting | Sponsor: Implicit Bioscience

New P1/2 trial • Cardiomyopathy • Cardiovascular

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. (PubMed, EClinicalMedicine) - P2 | "Using an adaptive platform design created to rapidly evaluate investigational agents, hospitalised patients with severe COVID-19 requiring ≥6 L/min oxygen were randomised to either a backbone regimen of dexamethasone and remdesivir alone (controls) or backbone plus one open-label investigational agent...The first 7 agents evaluated were cenicriviroc (CCR2/5 antagonist; n = 92), icatibant (bradykinin antagonist; n = 96), apremilast (PDE4 inhibitor; n = 67), celecoxib/famotidine (COX2/histamine blockade; n = 30), IC14 (anti-CD14; n = 67), dornase alfa (inhaled DNase; n = 39) and razuprotafib (Tie2 agonist; n = 22)...Funding for this trial has come from: the COVID R&D Consortium, Allergan, Amgen Inc., Takeda Pharmaceutical Company, Implicit Bioscience, Johnson & Johnson, Pfizer Inc., Roche/Genentech, Apotex Inc., FAST Grant from Emergent Venture George Mason University, The DoD Defense..."

Journal • P2 data • Acute Lung Injury • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CCR2 • CD14

Safety and Activity of Anti-CD14 Antibody IC14 (atibuclimab) in ALS: Experience with Expanded Access Protocol. (PubMed, Muscle Nerve) - "Administration of IC14 in ALS was safe and well-tolerated in this intermediate-size EAP. Measuring RO guided dosing frequency. Additional placebo-controlled trials are required to determine the efficacy of IC14 in ALS."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • CD14

Safety and Activity of Anti-CD14 Antibody IC14 (Atibuclimab) in ALS: Experience with an Expanded Access Protocol (ANA 2022) - "IC14 administration to ALS patients was safe and well tolerated in this EAP, with no significant changes in laboratory tests and no drug-related SAEs. Measuring RO Program and Abstracts, American Neurological Association S201 guided dosing frequency. Preliminary data suggest IC14 enhanced T-reg activity."

Clinical • Amyotrophic Lateral Sclerosis • CNS Disorders • CD14

COVID-19 and Anti-CD14 Treatment Trial (clinicaltrials.gov) - P2 | N=40 | Terminated | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | N=300 ➔ 40 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2021 ➔ Feb 2022; Stopped to slow rate of enrollment

Enrollment change • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. (PubMed, Medicine (Baltimore)) - P1b | "IC14 quickly and durably saturated its target in all patients. This study demonstrated safety and tolerability in patients with amyotrophic lateral sclerosis. Even though only a single cycle of treatment was given, there were promising beneficial trends in the neurofilament light chain, a disease biomarker. The emerging understanding of the role of systemic inflammation in neurodegenerative diseases, and the potential for IC14 to serve as a safe, potent, and broad-spectrum inhibitor of immune dysregulation merits further clinical study."

Clinical • Journal • P1 data • PK/PD data • Amyotrophic Lateral Sclerosis • CNS Disorders • Immunology • Inflammation • CD14 • CSF NfL

NIH trial of anti-CD14 antibody to treat COVID-19 respiratory disease begins (National Institute of Health) - "A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun....The laboratory-created monoclonal antibody, called IC14, binds to a human protein, CD14...Volunteer participants will be assigned at random to receive intravenous infusions of either IC14 or a placebo for four days....All participants will also receive intravenous infusions of the antiviral drug remdesivir for five consecutive days. The study team will follow participants for 60 days. Results are expected in early 2022."

P2 data • Trial status • Infectious Disease • Novel Coronavirus Disease

COVID-19 and Anti-CD14 Treatment Trial (clinicaltrials.gov) - P2; N=300; Recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 and Anti-CD14 Treatment Trial (clinicaltrials.gov) - P2; N=300; Not yet recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Trial completion date: Sep 2021 ➔ Jan 2022; Initiation date: Jul 2020 ➔ Feb 2021; Trial primary completion date: Jul 2021 ➔ Oct 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Controlled Study of IC14 for Treatment of ALS (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Implicit Bioscience; N=480 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders • Pain

IC14 for Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Implicit Bioscience; N=50 ➔ 0; Trial completion date: Dec 2020 ➔ Dec 2021; Not yet recruiting ➔ Withdrawn; Trial primary completion date: May 2020 ➔ May 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders • Pain • CD14

Healey ALS Platform Trial: IC14 Arm (clinicaltrials.gov) - P2; N=480; Not yet recruiting; Sponsor: Implicit Bioscience

Clinical • New P2 trial • Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders • Pain

IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19) (clinicaltrials.gov) - P2; N=300; Not yet recruiting; Sponsor: Implicit Bioscience

Clinical • New P2 trial • Novel Coronavirus Disease

Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) (clinicaltrials.gov) - P; N=N/A; Available; Sponsor: Implicit Bioscience

Clinical • New trial • Infectious Disease • Novel Coronavirus Disease

IC14 for ALS Patients Expanded Access (clinicaltrials.gov) - P; N=N/A; No Longer Available; Sponsor: Implicit Bioscience

Clinical • New trial